Big Data Supports Best Practices in CT Imaging

 By McKenna Bryant 

Complex datasets derived from artificial intelligence and machine learning capabilities inform precision medicine and improve operational efficiency.1  In furtherance of supporting best practices in CT imaging, NEXO® Contrast Management System could contribute to the growing body of research in the procurement of such rich data which may play a more significant role in the clinical field in the future.

One area where data collection efforts have proved useful is in CT contrast and radiation protocol management. Radiology enterprises commonly manage many CT imaging protocols, each containing numerous technical parameters tailored to specific diagnostic purposes or scanner models. But the constant need for protocol changes, combined with broad fleets of machines located throughout large healthcare networks, makes protocol management a daunting task.

In recent years, integrated, server-based software solutions have been developed to support protocol management efforts. At a recent expert panel meeting, Daniele Marin, MD, medical director of the Multi-Dimensional Image Processing Laboratory at Duke University School of Medicine, described his institution’s success with Bracco’s SmartInject Technology, powered by the NEXO Contrast Management Solution.

“We recently implemented this software, which has been advantageous because of its ability to integrate at multiple levels. It communicates with injectors in CT and MR, as well as with PACS, RIS, and EMR systems,” Dr. Marin said.

“We can collect information about a specific patient from our EMR system and send it to the NEXO server, and we can collect injection protocol information from a particular patient at the point of care. Our institution is fairly complex, with multiple sites and numerous scanners, and this has helped us overcome many challenges with protocol management.”

NEXO® Contrast Management Solution features a multi-injector control with seamless connectivity for smoother workflow, easy access to patient past records, protocol management for centralized, standardized quality and compliance, and key performance indicators for tracking and analyzing metrics.

NEXo SmartInject Solutions Network

More information available at: Bracco Diagnostics Inc.

Ryan Lee, MD, section chief of Neuroradiology and Vice Chair of Safety and Quality at Einstein Healthcare Network, agreed that there are numerous benefits to implementing an integrated data management system, including the ability to access radiation dose and contrast injection protocols.

“Having one integrated software solution that looks at radiation and contrast, instead of two, could be very valuable because you could retrospectively look at the data together and potentially that would accelerate how these software solutions work,” said Dr. Lee.

The advantages of data collection software extend beyond multi-system integration, Dr. Marin notes. “I think it has benefited us from a quality standpoint. We are more consistent in the way we implement protocols at different sites. Duke is moving toward freestanding imaging facilities in the area. It would be hard to control and ensure consistency if you don’t have a system that can help you with that,” he said.

Prior to implementing the NEXO solution, protocol modifications and rollouts were performed manually by chief technologists at each scanner. “The fact that you can do it remotely, from a time-saving standpoint, is huge. It also minimizes the potential risk for errors,” Dr. Marin emphasized.

At New York University Langone Health, Emilio Vega, manager of CT Quality and Safety, believes one of the most useful features of data collection software is the ability to refer to the information after completion of an examination. Click to view the video and learn more.

The future of big data collection is promising, and radiology departments are well-positioned to take advantage of emerging techniques by virtue of their robust technological infrastructure. “There is no question that big data is going to be the future,” Dr. Marin noted. “The growth rate of this technology in medicine is outpacing that of a lot of other areas of our society. So, we will see more and more of this big data in radiology moving forward.” Click the video to hear Dr. Marin.

Bracco’s SmartInject Technology, powered by NEXO® Contrast Management Solution, is an enterprise-wide server, that streamlines contrast media reporting and documentation. Learn how you can fine tune clinical workflow and increase productivity at Bracco Diagnostics, Inc.
References:
  1. Choy G, Khalilzadeh O, Michalski M, et al. Current applications and future impact of machine learning in radiology. Radiology. August 2018; 288: 318-328.
The views, information, or opinions expressed in the video(s) or article(s) above are solely those of the individuals involved and do not necessarily represent those of Bracco Diagnostics Inc. (“BDI”). The primary purpose of this video(s) or article(s) is to educate and inform. This information does not constitute medical or other professional advice or services.

EmpowerCTA®+ Injector System

Caution: Federal law restricts this device to sale by or on the order of a physician.

INDICATIONS:

The EmpowerCTA®+ Injector System is indicated for the vascular administration of contrast and flushing media in conjunction with computed tomography (CT) scanning of the body with an optional interface to a CT scanner and an optional calculator for glomerular filtration rate (GFR).

The Extravasation Detection Accessory (EDA™) is an optional accessory and is indicated for the detection of extravasations of ionic and nonionic contrast during CT procedures using a power injector.

Protocols have been independently developed and are not intended as medical advice. Bracco and Bracco Injeneering S.A. shall not be responsible for any physicians’ reliance on these or any other products.

 

CONTRAINDICATIONS:

The EmpowerCTA®+ Injector System is not intended for use as a long-term infusion pump, nor is it intended to be used to inject any agents other than contrast or flushing media. Do not attempt to use the Injector for any other purpose (such as chemotherapy or drug infusion). The EmpowerCTA+ Injector System should not be used to inject substances into nonvascular body cavities. Any applications of the EmpowerCTA+ Injector System other than those described in its Operator Manual are inappropriate and should not be attempted.

Not all products available in all global markets.

EmpowerCTA+ is distributed by Bracco Diagnostics Inc.; 259 Prospect Plains Road, Bldg. H; Monroe Township, NJ 08831 USA; Phone: (800) 631-5245; Fax: (609) 514-2424; Customer Service: 1-877-BRACCO 9 (1-877-272-2269); Professional Services: 1-800-257-5181 (Option 2); EmpowerCTA+ Email: empowerinfo@diag.bracco.com; Website: https://www.braccoimaging.com/us-en/products/injectors-informatics/empowercta

EmpowerCTA+ is manufactured for Bracco Injeneering S.A., Avenue de Sevelin 46, CH – 1004 Lausanne, Switzerland. http://imaging.bracco.com

 

EmpowerMR® Injector System

Caution: Federal law restricts this device to sale by or on the order of a physician.

INDICATIONS:

The EmpowerMR® Injector System is indicated for vascular administration of contrast media and flushing media in conjunction with magnetic resonance imaging (MRI).

Protocols have been independently developed and are not intended as medical advice and Bracco shall not be responsible for any physicians’ reliance on these or any other protocols.

Bracco Injeneering S.A. reserves the right at any time and without notice, to change the specifications and features described herein, or to change the production or adjust the product described.

Not all products available in all global markets.

EmpowerMR is distributed by Bracco Diagnostics Inc.; 259 Prospect Plains Road, Bldg. H; Monroe Township, NJ 08831 USA; Phone: (800) 631-5245; Fax: (609) 514-2424; Customer Service: 1-877-BRACCO 9 (1-877-272-2269); Professional Services: 1-800-257-5181 (Option 2); Website: https://www.braccoimaging.com/us-en/products/injectors-informatics/empowermr

EmpowerMR is manufactured by Bracco Injeneering S.A., Avenue de Sevelin 46, CH – 1004 Lausanne, Switzerland. http://imaging.bracco.com

 

NEXO® Contrast Management System

Intended Use:

The NEXO® Contrast Management System is a server-based application intended to be used as a data-management and visualization system. The NEXO Contrast Management System is able to read, store, share, compare/relate, as well as graphically display data and injection programs coming from RIS, PACS and multiple enabled EmpowerCTA® Injector Systems. This device provides users with record-lists, graphics and reports about data and performances.

This device is intended for retrospective and statistical data management and visualization. It is not intended for real-time data visualization, diagnostic applications or for any other use for which the device is not indicated. This device is only to be operated by and under quasi-continuous supervision of qualified and trained staff in an appropriate licensed healthcare facility.

The NEXO Contrast Management System is compatible with the EmpowerCTA Injector System version 8.0, and EmpowerCTA®+ Injector System version 9.0 and higher.

Bracco Injeneering S.A. reserves the right at any time and without notice, to change the specifications and features described herein, or to change the production or adjust the product described.

Not all products available in all global markets.

NEXO is distributed by Bracco Diagnostics Inc.; 259 Prospect Plains Road, Building H; Monroe Township, NJ 08831 USA; Phone: (800) 631-5245; Fax: (609) 514-2424; NEXO Customer Service: 1-877-BRACCO 9 (1-877-272-2269); NEXO questions: Nexo.Answers@diag.bracco.com; NEXO U.S. Technical Service and Support: Phone: 888-670-7701; Fax: 609-514-2448; NEXO Email:  customer.support@acistmedical.com; Website: https://imaging.bracco.com/us-en/products/injectors-informatics/nexo

NEXO is manufactured by Bracco Injeneering S.A., Avenue de Sévelin 46, CH-1004 Lausanne, Switzerland. http://imaging.bracco.com

 

NEXO [DOSE]® Multi-Modality Radiation Informatics

Intended Use:

NEXO [DOSE]® Multi-Modality Radiation Informatics is a server-based application that acquires, stores, and reports radiation dose index data from medical imaging procedures.

NEXO [DOSE] Multi-Modality Radiation Informatics is intended to be used by qualified medical personnel only.

NEXO [DOSE] is distributed by Bracco Diagnostics Inc.; 259 Prospect Plains Road, Building H; Monroe Township, NJ 08831 USA; Phone: (800) 631-5245; Fax: (609) 514-2424; NEXO [DOSE] Customer Service: 1-877-BRACCO 9 (1-877-272-2269); NEXO [DOSE] questions: Nexo.Answers@diag.bracco.com; Website: https://imaging.bracco.com/us-en/products/injectors-informatics/nexo-dose NEXO [DOSE] Technical Support provided by PACSHealth, L.L.C: 1-877-299-6587

NEXO [DOSE] is manufactured by and is licensed from PHS Technologies Group, L.L.C, 32531 N. Scottsdale Road, Suite #105-282, Scottsdale, AZ 85266; a wholly-owned subsidiary of PACSHealth, L.L.C.

Not all products available in all global markets.

 

About Bracco Injeneering S.A.

Bracco Injeneering S.A., located in Lausanne, Switzerland, is the most recently added Business Unit of Bracco Imaging. Bracco Injeneering is committed to develop the best-in-class integrated injection solutions with a strong heritage in research and innovation. It provides quality solutions for state-of-the-art radiology centers, offering proven injection technology, built on Bracco Imaging’s expertise.

Thanks to this strengthened product portfolio, including the CT Exprès® 3D Contrast Media Delivery System, EmpowerCTA+ Injector System, EmpowerMR Injector System, NEXO Contrast Management System and NEXO [DOSE] Multi-Modality Radiation Informatics, Bracco Imaging will be able to focus on constant innovation, not only for devices, but also for software development and data management.

CT Exprès, EmpowerCTA, EmpowerMR, IRiSCT, NEXO and NEXO [DOSE] are registered trademarks of Bracco Injeneering S.A.

EDA and FastLoad are trademarks of Bracco Injeneering S.A.

These are representative images from reference studies; individual results may vary.

© 2022 Bracco Diagnostics Inc. All Rights Reserved.